Enprofylline

Enprofylline belongs to the pharmacological class Methyl Xanthines. Enprofylline appears to have bronchodilatory effects in the pulmonary system. Enprofylline is rapidly mediated through competitive inhibition of phosphodiesterase which in turn results in increase in cyclic AMP thereby producing relaxation of bronchial smooth muscle as well as antagonistic effect of adenosine receptors.

Enprofylline has been found to be approved for relieving symptoms and for the treatment and maintenance of episodes of asthma, bronchospasm Chronic Obstructive Pulmonary Disease, cerebrovascular insufficiency, sickle cell disease, and diabetic neuropathy .

Enprofylline is rapidly absorbed after oral administration. Metabolism of Enprofylline is mainly hepatic route. The half life of Enprofylline is approximately 2 hours. The route of the elimination of Enprofylline is primarily 80% through urine.

Enprofylline is available in the form of oral tablets.

Enprofylline is available in U.S., Canada,E.U. , India, Australia, Japan.

Enprofylline belongs to the pharmacological class of Methylxanthines. Enprofylline appears to have bronchodilator effects in the pulmonary system.

Enprofylline is rapidly mediated through competitive inhibition of phosphodiesterase which in turn results in increase in cyclic AMP thereby producing relaxation of bronchial smooth muscle as well as antagonistic effect of adenosine receptors.

Enprofylline has found to be approved for relieving symptoms and for the treatment and maintenance of episodes asthma, bronchospasm, Chronic Obstructive Pulmonary Disease cerebrovascular insufficiency, sickle cell disease, and diabetic neuropathy.

Enprofylline can be used in the treatment of:

• Asthma
• Bronchospasm
• Chronic Obstructive Pulmonary Disease
• Cerebrovascular insufficiency
• Sickle cell disease
• Diabetic neuropathy.

Enprofylline is approved for use in the following clinical indications:

• Asthma
• Bronchospasm
• Chronic Obstructive Pulmonary Disease.
• Cerebrovascular insufficiency
• Sickle cell disease
• Diabetic neuropathy.

Tablet is to be swallowed with water as a whole.

Oral tablets

Maintaining health and smoking cessation and is a must.

In take of Caffeine is to be avoided or limited to use as it may lead to the risk of nervousness, rapid heartbeat, nausea, palpitationsetc.

Alcohol should be avoided in the patient especially in pateints with an underlying liver disorder or liver dysfunction

Diet containing food with a salt, preservatives, refined and high energy-dense foods, high glycemic index, red and processed meat, added sugar, saturated and trans fat food, low fiber, low antioxidants, and vitamins is to be restricted.

The dietary restrictions should be individualized as per the patient's requirements.

Enprofylline may be contraindicated under the following conditions:

• Hypersensitivity to the ingredients of the medication

Physician should be vigilant and knowledgeable about the treatment pertaining to the identification and treatment of overdosage of Enprofylline.

There has found to be no reports pertaining to the overdosage information related to Enprofylline medication.

Pharmacodynamics

Enprofylline is a synthetic dimethylxanthine derivative structurally related to theophylline and caffeine. It antagonizes erythrocyte phosphodiesterase, increasing cAMP activity.

• https://www.ndrugs.com/?s=enprofylline
• https://go.drugbank.com/drugs/DB00824
• https://pubchem.ncbi.nlm.nih.gov/compound/Enprofylline#section=Depositor-Supplied-Synonyms
• https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:126237
• https://onlinelibrary.wiley.com/doi/abs/10.1111/j.1600-0773.1988.tb00936.x
• Nielsen-Kudsk, J. E., & Askholt, J. (1988). Pharmacodynamics and Pharmacokinetics of Enprofylline and Theophylline in the Isolated Rabbit Heart. Pharmacology & Toxicology, 63(3), 183–188.